Indian contract research, development and manufacturing (CRDMO) company providing drug discovery, development and manufacturing services to global pharma/biotech clients.
Indian contract research, development and manufacturing (CRDMO) company providing drug discovery, development and manufacturing services to global pharma/biotech clients.
In one line: India's smaller Lonza/Catalent.
Moat: narrow (process know-how, customer qualification, regulatory licence). Regulatory-approved manufacturing facilities and scientific expertise create switching costs for pharma clients.
Headquarters: Bengaluru, India · Founded: 2006 · Employees: 3,302
Size Anthem Biosciences (ANTHEM.NS) is an India Health Care company (Biotechnology) with a market value of $5.51B, the 200th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹914.35 on 18 Nov 2026.
Performance Over six months the shares gained 16.1%, against -3.5% for the median peer and +3.8% for the India market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 1.2% over the last twelve months (peer median +2.4%); the operating margin is 34.8% (peer median -18.9%).
Valuation It trades at 64.3× forward earnings against a peer median of 53.7× (4th cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 9.6 points above its cost of capital (10.8% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹20.5B | ₹21.2B | ₹18.4B | ₹14.2B | ₹10.6B |
| Revenue growth | — | +15% | +30% | +34% | — |
| Gross profit | ₹9.20B | ₹7.97B | ₹6.70B | ₹5.06B | ₹4.49B |
| EBITDA | ₹8.46B | ₹8.61B | ₹6.83B | ₹5.15B | ₹4.35B |
| Net income | ₹6.14B | ₹5.92B | ₹4.51B | ₹3.67B | ₹3.85B |
| Free cash flow | n/a | ₹7.06B | ₹644M | -₹1.18B | ₹1.54B |
| Capital expenditure | n/a | ₹2.11B | ₹2.61B | ₹2.97B | ₹1.95B |
| Total debt | ₹412M | ₹539M | ₹1.13B | ₹2.39B | ₹1.26B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Anthem Biosciences ANTHEM.NS | $5.51B | +16% | -1% | 35% | 64.3× | 36.9% |
| Syngene International SYNGENE.NS | $1.88B | -8% | -6% | 13% | 70.7× | 36.4% |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
| Laurus Labs LAURUSLABS.NS | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANTHEM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.1% | -3.4% | 6th highest of 21 |
| 6-month return | +16.1% | -3.5% | 8th highest of 21 |
| Distance from 52-week high | -7.6% | -32.6% | highest of 21 |
| Revenue growth (TTM) | -1.2% | +2.4% | 8th highest of 15 |
| Operating margin | 34.8% | -18.9% | 2nd highest of 16 |
| Forward P/E | 64.3× | 53.7× | 4th cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 36.9% | 25.9% | 2nd most demanding of 6 |
| Growth delivered (Del g) | +26.2% | +16.4% | 2nd highest of 6 |
| Hurdle (Req g minus delivered) | +10.7 pp | +9.4 pp | 3rd most demanding of 6 |
| ROIC minus cost of capital | +9.6 pp | -11.2 pp | 3rd highest of 12 |
| EV / EBITDA | 60.1× | n/a | — |
| Net debt / EBITDA | -0.8× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 64.3× | 36.9% | +26.2% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 79.4× | 18.2% | +61.5% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | n/a | -6.5% | -10.0% |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 97.0× | 25.9% | +16.4% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | n/a | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 12.8× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 30.3× | 32.4% | +7.1% |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 77.1× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 12.0× | n/a | n/a |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | n/a | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | n/a | 47.2% | +16.6% |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | n/a | n/a | n/a |